Compare Supplements

No legitimate self-administration dose exists. Japan's approved DIAGNOSTIC use is a single 100 µg IV dose for a GH-stimulation test. Grey-market injectable protocols (~100 µg subcutaneous, 1-3×/day) are unapproved and unvalidated.

Any time

None — diagnostic IV use is clinician-administered; there is no validated self-use form

No validated human dose for any physique or anti-aging use exists. In clinical research GHRP-6 has been given as a single ~1 mcg/kg dose for provocative GH/HPA-axis testing, and at 100-400 mcg/kg in single-dose pharmacokinetic work. Anecdotal grey-market 'GH-boosting' protocols circulate online but have no clinical basis, no efficacy validation, and should not be read as a recommendation.

Any time

None — no form has validated human efficacy or an approved standard

• Pregnancy / breastfeeding (avoid — not studied)
• Active or history of cancer (GH/IGF-1 elevation is a theoretical proliferation concern)
• Diabetes / impaired glucose tolerance (GH secretagogues can reduce insulin sensitivity)

• Insulin / antidiabetic drugs
• Corticosteroids
• Thyroid / other pituitary-axis hormones

• Pregnancy and breastfeeding — never studied; avoid entirely
• Active cancer or history of cancer — GH/IGF-1 elevation is a theoretical proliferative concern, never evaluated for this peptide in humans
• Diabetes / impaired glucose tolerance — GH excess promotes insulin resistance, and the peptide stimulates appetite

• Insulin / glucose-lowering drugs
• Corticosteroids